Prophylactic platelet transfusions

Pietersz, R. N. I.; Reesink, H. W.; Panzer, Simon; Gilbertson, Moyna P.; Borosak, Marija; Wood, Erica M.; Leitner, Gerda; Rabitsch, Werner; Ay, Cemil; Lambermont, Micheline; Deneys, Véronique; Sondag, D.; Compernolle, Veerle; Legrand, Delphine; François, Anne Isabelle; Tardivel, R.; Garban, Frédéric; Sawant, Rajesh B; Rebulla, Paolo; Handa, Makoto; Hitoshi, Ohto; Kerkhoffs, J.L.; Brand, A.; Жибурт, Е Б; Cid, Joan; Escolar, Ginés; Lozano, Miquel; Puig, L.; Knutson, Folke; Hallböök, Heléne; Lübenow, Norbert; Estcourt, Lise J; Stanworth, S; Murphy, M. F.; Williams, Lynne; Mraz, D. L.; Ross, Rebecca; El, Snyder

doi:10.1111/j.1423-0410.2012.01595.x

Cited by 12 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another possible application of this optimized flow cytometry–based assay is to function as a tool for predicting the individual threshold of patients with thrombocytopenia for prophylactic transfusion. The majority of PLT transfusions are administered as prophylaxis in patients with low PLT counts to reduce the risk of bleeding . Based on several studies the threshold has been set at 10 × 10 9 /L PLTs, and this has remained the standard ever since.…”

Section: Discussionmentioning

confidence: 99%

Functional recovery of stored platelets after transfusion

et al. 2016

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Functional recovery of stored platelets after transfusion

et al. 2016

View full text Add to dashboard Cite

show abstract

“…PC specifications vary significantly from country to country. Variations include: the proportion of patients receiving apheresis platelets (van der Poel et al , ,b,c,d); the proportion who suspend platelets in platelet additive solutions or plasma (Pietersz et al , ); and the platelet dose within each PC (Pietersz et al , ). When we consider changes to components that may affect the number of PCs used.…”

Section: Changes To Product Specificationmentioning

confidence: 99%

Why has demand for platelet components increased? A review

Estcourt

2014

Transfusion Medicine

View full text Add to dashboard Cite

Platelet transfusions are used in clinical practice to prevent and treat haemorrhage in thrombocytopenic patients or patients with severe platelet dysfunction. In the UK, and abroad there has been a recent rise in platelet component demand. The three largest patient groups that use platelet components are patients with haematological malignancies (up to 67%), patients receiving cardiac surgery (up to 10%) and patients receiving intensive care (up to 8%). This review has explored some of the factors that may explain this recent trend within these three main groups. These factors include a rise in the general population, an ageing population, an increase in the incidence and prevalence of haematological malignancies, and changes in the management of patients with haematological malignancies. However, the only data available that can be correlated directly with national component data are the size of the total population. There is no evidence to support the premise that use of platelet components in patients receiving cardiac surgery or intensive care treatment is rising over and above the general rise in the population, but the data are sparse.

show abstract

“…Increasing the dose from a standard to a high dose did not increase the transfusion interval (median 5 days for both regimens). The mean UK adult platelet dose (one unit of platelets) is around 3 × 10 11 platelets, equivalent to between the low and standard doses defined above, although there is evidence of considerable variation (Pietersz et al , ).…”

Section: Prophylactic Transfusion Of Platelets To Patients With Thrommentioning

confidence: 99%